Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07215494) titled 'A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis' on Oct. 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Peking University First Hospital
Condition:
Light Chain (AL) Amyloidosis
MRD
Intervention:
Drug: First-Line Dara-BorCyD Treatment
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: October 2025
Target Sample Size: 50
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NC...